- Risk Benefit Case Studies and Models
- Warfarin Pharmacogenomics Risk-Benefit Analysis Case Study
- Gene Expression Profiling in Early-Stage Breast Cancer
- GEP in Early-Stage Breast Cancer Model
GEP in Early-Stage Breast Cancer Model
Model Introduction and Explanation
This GEP in early-stage breast cancer risk-benefit analysis model is intended to serve as a tool for stakeholders to evaluate the potential impact of GEP versus NCCN guidelines in terms of clinical events (i.e. distant recurrences and life expectancy) and quality-adjusted life years (QALY) (i.e. QALYs lost due to adverse events, QALYs lost due to distant recurrence, and total QALYs). The model is structured in a manner that allows the user to specify the baseline patient cohort age, cohort size, average baseline distant recurrence risk, average chemotherapy relative risk reduction, risk stratum specific chemotherapy uptake rates, and health state utility values. Based on these inputs, the model calculates long-term health outcomes.
The model version available below is a beta-version. This version is being released to facilitate user feedback for refinement of the final model. Please share your feedback with David Veenstra, PharmD, PhD at email@example.com or Joshua Roth, MHA at firstname.lastname@example.org.
Download the GEP in early-stage breast cancer model in Excel spreadsheet form.*
*Click the hyperlink above to download the gene expression profiling in early-stage breast cancer risk-benefit analysis model. This action should save the model to the default location on your hard drive for internet downloads (e.g. desktop or documents folder). Once the model is saved on your hard drive, you can open the excel file, change model inputs, and save changes to the model.